Top

Published in:

01-10-2007 | Original Research Article

A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD

Authors: Laura Bojke, Edward Hornby, Mark Sculpher

Published in: PharmacoEconomics | Issue 10/2007

Abstract

Background: Gastro-oesophageal reflux disease (GORD) causes some of the most frequently seen symptoms in both primary and secondary care. An estimated 4–5 patients (age range 18–60 years) per 10 000 (0.045% of the general population) are receiving maintenance proton pump inhibitors (PPIs) for oesophagitis and reflux. The treatment of reflux disease represents significant prescription drug costs to the UK NHS. An alternative to lifelong pharmacotherapy is surgical treatment of reflux using the laparoscopic fundoplication technique to effect a cure. A multicentre study (REFLUX trial) comparing laparoscopic fundoplication with medical management (PPIs) among patients with GORD is currently underway in the UK. This study includes data collection to contribute to a cost-effectiveness analysis.

Objective: To generate some preliminary estimates of the cost effectiveness of surgical and medical management of GORD to guide UK NHS decision making before the REFLUX trial reports.

Methods: A Markov model was developed in Excel. Probabilistic sensitivity analysis was employed to assess the uncertainty associated with the point estimates. Two strategies were compared: long-term medical management or immediate laparoscopic surgery for GORD. Health outcomes were expressed in terms of QALYs with a lifetime time horizon (30 years) for a patient aged 45 years at commencement of treatment. Costs (£, 2004 values) of drugs and costs associated with surgery were obtained from five of the REFLUX study centres. Costs and outcomes were discounted by 3.5% per anum.

Value of information analysis was used to quantify the cost of uncertainty associated with the decision about which therapy to adopt, indicating the maximum value of future research.

Results: Treatment with laparoscopic fundoplication is the most costly strategy but is also associated with more QALYs. The incremental cost per additional QALY for surgery versus medical management was £180. However, the cost effectiveness of surgery was uncertain, and the probability that it is cost effective at the threshold of £30 000 per QALY was 0.639. Value of information analysis suggests that further research in this area could be potentially worthwhile. Specifically, this research should focus on the health-related quality of life of patients on medical management or post-surgery.

Conclusions: The results of the model suggest that, on the basis of current evidence, laparoscopic fundoplication represents a cost effective means of treating GORD rather than lifelong medical management.

Available only for authorised users

Dent J, Talley NJ. Overview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 53–57PubMedCrossRef

McDougall NI, Johnston BT, kee F, et al. Natural history of reflux oesophagitis: a 10-year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481–486PubMedCrossRef

Leuflcens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11: 887–897CrossRef

Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43 (2): 253–257PubMedCrossRef

Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104 (5): 422–430PubMedCrossRef

Trimble KC, Douglas S, Pryde A, et al. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40: 1098–1104PubMedCrossRef

Carlson MA, Frantzides CT. Complications and results of primary minimally invasive antireflux procedures: a review of 10735 reported cases. J Am Coll Surg 2001; 193: 428–439PubMedCrossRef

Viljakka M, Nevalainen J, Isolauri J. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand J Gastroenterol 1997; 32: 766–772PubMedCrossRef

Coley CM, Barry MJ, Spechler SJ, et al. Initial medical v surgical therapy for complicated or chronic gastroesophageal disease (GERD): a cost effectiveness analysis. Gastroenterology 1993; 104 (4): A

10.

Van Den Boom BG, Go PM, Hameeteman W, et al. Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Scand J Gastroenterol 1996; 31: 1–9CrossRef

11.

Nessen SC, Holcomb J, Tonkinson B, et al. Early laparoscopic Nissen fundoplication for recurrent reflux esophagitis: a cost-effective alternative to omeprazole. JSLS 1999; 3: 103–106PubMed

12.

Romagnuolo J, Meier MA, Sadowski DC. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model. Ann Surg 2002; 236: 191–202PubMedCrossRef

13.

Cookson R, Flood C, Koo B, et al. Short-term cost-effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg 2005; 92: 700–706PubMedCrossRef

14.

Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106–110PubMedCrossRef

15.

Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155 (14): 1465–1471PubMedCrossRef

16.

Wileman S, McLeer S, Campbell MK, et al. Laparoscopic fundoplication versus medical management for gastro-oesophageal reflux disease (GORD) in adults (Protocol for a Cochrane review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2002

17.

Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–721PubMedCrossRef

18.

Detsky AS, Naglie IG. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147–154PubMed

19.

HM Treasury. Green book: appraisal and evaluation in central government. London: HM Treasury, 2003

20.

Contini S, Zinocola R, Bertele A, et al. Dysphagia and clinical outcome after laparoscopic Nissen or Rossetti fundoplication: sequential prospective study. World J Surg 2002; 26 (9): 1106–1111PubMedCrossRef

21.

Gotley DC, Smithers BM, Rhodes M, et al. Laparoscopic Nissen fundoplication: 200 consecutive cases. Gut 1996; 38 (4): 487–491PubMedCrossRef

22.

Dallemagne B, Weerts JM, Jeahes C, et al. Results of laparoscopic Nissen fundoplication. Hepatogastroenterology 1998; 45: 1338–1343PubMed

23.

Kiviluoto T, Siren J, Farkkila M, et al. Laparoscopic Nissen fundoplication: a prospective analysis of 200 consecutive patients. Surg Laparosc Endosc 1998; 8: 429–434PubMedCrossRef

24.

Booth MI, Jones L, Stratford J, et al. Results of laparoscopic Nissen fundoplication at 2–8 years after surgery. Br J Surg 2002; 89: 476–481PubMedCrossRef

25.

Landreneau RJ, Wiechmann RJ, Hazelrigg SR, et al. Success of laparoscopic fundoplication for gastroesophageal reflux disease. Ann Thorac Surg 1998; 66: 1886–1893PubMedCrossRef

26.

Finley CR, McKernan JB. Laparoscopic antireflux surgery at an outpatient surgery center. Surg Endosc 2001; 15: 823–826PubMedCrossRef

27.

Pessaux P, Arnaud JP, Ghavami B, et al. Morbidity of laparoscopic fundoplication for gastroesophageal reflux: a retrospective study about 1470 patients. Hepatogastroenterology 2002; 49: 447–450PubMed

28.

van der Peet DL, Klinkenberg-Knol EC, Eijsbouts QAJ, et al. Laparoscopic Nissen fundoplications for the treatment of gastroesophageal reflux disease (GERD). Surg Endosc 1998; 12: 1159–1163PubMedCrossRef

29.

Bais JE Bartelsman JFWM, Bonjer HJ, et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. Lancet 2000; 355: 1704CrossRef

30.

Office for National Statistics. Key population and vital statistics. London: Her Majesty’s Stationery Office, 2003

31.

Anvari M, Allen C. Five-year comprehensive outcomes evaluation in 181 patients after laparoscopic Nissen fundoplication. J Am Coll Surg 2003; 196: 51–57PubMedCrossRef

32.

Watson DI, Jamieson GG, Devitt PG, et al. Changing strategies in the performance of laparoscopic Nissen fundoplication as a result of experience with 230 operations. Surg Endosc 1995; 9: 961–966PubMed

33.

Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172–179PubMedCrossRef

34.

Lundell L, Abrahamsson H, Ruth M, et al. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Touplet) for gastro-oesophageal reflux. Br J Surg 1996; 83: 830–835PubMedCrossRef

35.

Ludemann R, Watson DI, Jamieson GG, et al. Five-year follow-up of a randomized clinical trial of laparoscopic total versus anterior 180 fundoplication. Br J Surg 2005; 92: 240–243PubMedCrossRef

36.

Hunter JG, Smith DC, Branum GD, et al. Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg 1999; 230: 595–606PubMedCrossRef

37.

Graziano K, Teitelbaum DH, McLean K, et al. Recurrence after laparoscopic and open Nissen fundoplication: a comparison of the mechanisms of failure. Surg Endosc 2003; 17: 704–707PubMedCrossRef

38.

Soper NJ, Dunnegan D. Anatomic fundoplication failure after laparoscopic antireflux surgery. Ann Surg 1999; 229: 669–676PubMedCrossRef

39.

Jamieson GG, Watson DI, Britten-Jones R, et al. Laparoscopic Nissen fundoplication. Ann Surg 1994; 220: 137–145PubMedCrossRef

40.

Eshraghi N, Farahmand M, Soot SJ, et al. Comparison of outcomes of open versus laparoscopic Nissen fundoplication performed in a single practice. Am J Surg 1998; 175: 371–374PubMedCrossRef

41.

Bammer T, Hinder RA, Klaus A, et al. Five- to eight-year outcome of the first laparoscopic Nissen fundoplications. J Gastrointest Surg 2001; 5: 42–48PubMedCrossRef

42.

Hatlebakk JG, Berstad A. Lansoprazole 15 and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 365–372PubMedCrossRef

43.

Festen HP, Schenk E, Tan G, et al. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short and long-terra treatment. The Dutch reflux Study Group. Am J Gastroenterol 1999; 94: 931–936PubMedCrossRef

44.

Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis: Solo Investigator Group. Gut 1995; 36: 492–498PubMedCrossRef

45.

Myrvold HE, Lundell L, Miettinen P, et al. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 2001; 49: 488–494PubMedCrossRef

46.

British National Formulary 48. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, 2004

47.

Curtis L, Netten A. Unit costs of health and social care 2005. Canterbury: Personal Social Services Research Unit, 2005

48.

Johnston PW, Johnston BT, Collins B J, et al. Audit of the role of oesophageal manometry in clinical practice. Gut 1993; 34: 1158–1161PubMedCrossRef

49.

SwanstromL, Wayne R. Spectrum of gastrointestinal symptoms after laparoscopic fundoplication. Am J Surg 1994; 167: 538–541CrossRef

50.

Laine S, Rantala A, Gullichsen R, et al. Laparoscopic vs conventional Nissen fundoplication: a prospective randomized study. Surg Endosc 1997; 11: 441–444PubMedCrossRef

51.

Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996

52.

Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK general population survey [discussion paper 138]. York: University of York, Centre for Health Economics, 1995

53.

Kind P, Hardman G, Macran S. UK population Norms for EQ-5D [discussion paper 172]. York: University of York, Centre for Health Economics, 1999

54.

Ainslie WG, Catton JA, Davides D, et al. Micropuncture cholecystectomy vs conventional laparoscopic cholecystectomy. Surg Endosc 2003; 17: 766–772PubMedCrossRef

55.

Heudebert GR, Marks R, Wilcox CM, et al. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112: 1078–1086PubMedCrossRef

56.

Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479–500PubMedCrossRef

57.

Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3: 309–319PubMedCrossRef

58.

Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779–789PubMedCrossRef

59.

Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling [discussion paper 179]. York: University of York, Centre for Health Economics, 2000

60.

Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341–364PubMedCrossRef

61.

Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002; 360: 711–715PubMedCrossRef

Title: A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
Authors: Laura Bojke
Edward Hornby
Mark Sculpher
Publication date: 01-10-2007
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 10/2007
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200725100-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

Valuing Children’s Health

Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin

Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients

Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions